277 related articles for article (PubMed ID: 27650951)
1. Long-Range Chromatin Interactions Drive Mutant TERT Promoter Activation.
Akıncılar SC; Khattar E; Boon PL; Unal B; Fullwood MJ; Tergaonkar V
Cancer Discov; 2016 Nov; 6(11):1276-1291. PubMed ID: 27650951
[TBL] [Abstract][Full Text] [Related]
2. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.
Min J; Shay JW
Cancer Discov; 2016 Nov; 6(11):1212-1214. PubMed ID: 27807101
[TBL] [Abstract][Full Text] [Related]
3. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
Stern JL; Theodorescu D; Vogelstein B; Papadopoulos N; Cech TR
Genes Dev; 2015 Nov; 29(21):2219-24. PubMed ID: 26515115
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
[No Abstract] [Full Text] [Related]
5. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.
Shi Z; Ge X; Li M; Yin J; Wang X; Zhang J; Chen D; Li X; Wang X; Ji J; You Y; Qian X
Mol Cell; 2022 Oct; 82(20):3919-3931.e7. PubMed ID: 36270249
[TBL] [Abstract][Full Text] [Related]
6. Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters.
Li Y; Tergaonkar V
Transcription; 2016 Mar; 7(2):44-9. PubMed ID: 27028424
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and GABP transcription factors in carcinogenesis: More foes than friends.
Yuan X; Dai M; Xu D
Cancer Lett; 2020 Nov; 493():1-9. PubMed ID: 32768523
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide screens identify specific drivers of mutant
Shanmugam R; Ozturk MB; Low JL; Akincilar SC; Chua JYH; Thangavelu MT; Periyasamy G; DasGupta R; Tergaonkar V
Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35027447
[TBL] [Abstract][Full Text] [Related]
9. Characterization of human telomerase reverse transcriptase promoter methylation and transcription factor binding in differentiated thyroid cancer cell lines.
Avin BA; Wang Y; Gilpatrick T; Workman RE; Lee I; Timp W; Umbricht CB; Zeiger MA
Genes Chromosomes Cancer; 2019 Aug; 58(8):530-540. PubMed ID: 30664813
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of FOS in mutant
Liu R; Tan J; Shen X; Jiang K; Wang C; Zhu G; Xing M
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836600
[TBL] [Abstract][Full Text] [Related]
11. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
12. Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
Li Y; Zhou QL; Sun W; Chandrasekharan P; Cheng HS; Ying Z; Lakshmanan M; Raju A; Tenen DG; Cheng SY; Chuang KH; Li J; Prabhakar S; Li M; Tergaonkar V
Nat Cell Biol; 2015 Oct; 17(10):1327-38. PubMed ID: 26389665
[TBL] [Abstract][Full Text] [Related]
13. CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.
Kumar M; Witt B; Knippschild U; Koch S; Meena JK; Heinlein C; Weise JM; Krepulat F; Kuchenbauer F; Iben S; Rudolph KL; Deppert W; Günes C
Int J Cancer; 2013 May; 132(9):2032-43. PubMed ID: 23023397
[TBL] [Abstract][Full Text] [Related]
14. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
15. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
Eldholm V; Haugen A; Zienolddiny S
Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
[TBL] [Abstract][Full Text] [Related]
16. GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X; Mu N; Wang N; Strååt K; Sofiadis A; Guo Y; Stenman A; Li K; Cheng G; Zhang L; Kong F; Ekblad L; Wennerberg J; Nilsson IL; Juhlin CC; Larsson C; Xu D
Oncogene; 2019 Feb; 38(7):965-979. PubMed ID: 30181547
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter mutations in cancer development.
Heidenreich B; Rachakonda PS; Hemminki K; Kumar R
Curr Opin Genet Dev; 2014 Feb; 24():30-7. PubMed ID: 24657534
[TBL] [Abstract][Full Text] [Related]
18. Allele-Specific DNA Methylation and Its Interplay with Repressive Histone Marks at Promoter-Mutant TERT Genes.
Stern JL; Paucek RD; Huang FW; Ghandi M; Nwumeh R; Costello JC; Cech TR
Cell Rep; 2017 Dec; 21(13):3700-3707. PubMed ID: 29281820
[TBL] [Abstract][Full Text] [Related]
19. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
20. Occurrence, functionality and abundance of the TERT promoter mutations.
Rachakonda S; Hoheisel JD; Kumar R
Int J Cancer; 2021 Dec; 149(11):1852-1862. PubMed ID: 34313327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
